Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Apogee Therapeutics, Inc.

APGE · — · CIK 0001974640 · Healthcare

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

38 Form 4 transaction lines observed in the same window
19 sales · 19 option, withholding, award, gift or other lines

Last qualifying purchase2024-12-12 · McKenna Mark C. · $990.8K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Dambkowski CarlChief Medical Officer
○▼○▼▼○▼○○▼○○
HENDERSON MICHAEL THOMASChief Executive Officer
▼▼▼▼○○
Henderson JaneChief Financial Officer
▼○○
Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasDirector
○○
Shah Nimish PDirector
○
McKenna Mark C.Director
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-12-12 · McKenna Mark C..

Recent Form 4 activity

0Purchases
82Sales
25Other Form 4 lines
47SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING19 sale line(s) · context only
OTHER19 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
—
3M
—
6M
—
12M
—

Volatility & liquidity

Volatility
—
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biological Products, (No Diagnostic Substances)

Market data

Price data up to: 2026-10-03 · Price source: OpenBB/yfinance · Status: PASS

Short interest

The FINRA report lists no short interest for this ticker.

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-12-12McKenna Mark C.Purchase (P)Common Stock20,000USD 49.54USD 990,775SEC filing ↗
2023-07-13Shah Nimish PPurchase (P)Common Stock1,750,000USD 17.00USD 29,750,000SEC filing ↗
2023-07-13Fairmount Funds Management LLC; Fairmount Healthcare Co-Invest II L.P.; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.; Harwin Peter Evan; Kiselak TomasPurchase (P)Common Stock2,941,176USD 17.00USD 49,999,992SEC filing ↗

Form 4 evidence

107 transaction lines in the latest 365-day window; 171 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-03Shah Nimish PD (D)Common Stock1,750,000USD 135.11USD 236,442,500SEC filing ↗
2026-09-03McKenna Mark C.D (D)Common Stock20,000USD —USD —SEC filing ↗
2026-09-03JONES WILLIAM A JRD (D)Common Stock34,824USD —USD —SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-03Shah Nimish PD (D)Common Stock1,750,000USD 135.11USD 236,442,500SEC filing ↗
2026-09-03McKenna Mark C.D (D)Common Stock20,000USD —USD —SEC filing ↗
2026-09-03JONES WILLIAM A JRD (D)Common Stock34,824USD —USD —SEC filing ↗
2026-09-03Henderson JaneD (D)Common Stock158,371USD —USD —SEC filing ↗
2026-09-03HENDERSON MICHAEL THOMASD (D)Common Stock920,941USD —USD —SEC filing ↗
2026-09-03Fox Jennifer A.D (D)Common Stock34,824USD —USD —SEC filing ↗
2026-09-03Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasD (D)Common Stock392,021USD —USD —SEC filing ↗
2026-09-03Dambkowski CarlD (D)Common Stock167,123USD —USD —SEC filing ↗
2026-09-02Dambkowski CarlD (D)Common Stock1,375USD 135.06USD 185,708SEC filing ↗
2026-08-07Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasOption exercise / conversion (M)Common Stock42,208USD 23.60USD 995,970SEC filing ↗
2026-08-05Dambkowski CarlSale (S)Common Stock5,500USD 134.17USD 737,935SEC filing ↗
2026-08-05Dambkowski CarlOption exercise / conversion (M)Common Stock4,125USD 22.86USD 94,298SEC filing ↗
2026-07-24Henderson JaneGift (G)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-07-14Dambkowski CarlGift (G)Common Stock8,000USD 0.00USD 0SEC filing ↗
2026-07-10HENDERSON MICHAEL THOMASGift (G)Common Stock75,046USD 0.00USD 0SEC filing ↗
2026-07-08HENDERSON MICHAEL THOMASSale (S)Common Stock20,000USD 133.63USD 2,672,600SEC filing ↗
2026-07-01Dambkowski CarlSale (S)Common Stock5,500USD 132.74USD 730,070SEC filing ↗
2026-07-01Dambkowski CarlOption exercise / conversion (M)Common Stock4,125USD 22.86USD 94,298SEC filing ↗
2026-06-22HENDERSON MICHAEL THOMASSale (S)Common Stock80,000USD 132.54USD 10,603,200SEC filing ↗
2026-06-22Dambkowski CarlSale (S)Common Stock26,400USD 132.60USD 3,500,640SEC filing ↗
2026-06-10HENDERSON MICHAEL THOMASSale (S)Common Stock20,000USD 83.38USD 1,667,622SEC filing ↗
2026-06-03Dambkowski CarlSale (S)Common Stock5,500USD 78.71USD 432,905SEC filing ↗
2026-06-03Dambkowski CarlOption exercise / conversion (M)Common Stock4,125USD 22.86USD 94,298SEC filing ↗
2026-05-13HENDERSON MICHAEL THOMASSale (S)Common Stock20,000USD 82.09USD 1,641,711SEC filing ↗
2026-05-06Dambkowski CarlSale (S)Common Stock5,500USD 84.14USD 462,784SEC filing ↗
2026-05-06Dambkowski CarlOption exercise / conversion (M)Common Stock4,125USD 22.86USD 94,298SEC filing ↗
2026-05-01Henderson JaneSale (S)Common Stock2,000USD 82.04USD 164,080SEC filing ↗
2026-04-16HENDERSON MICHAEL THOMASOption exercise / conversion (M)Common Stock3,000USD 22.86USD 68,580SEC filing ↗
2026-04-16Henderson JaneSale (S)Common Stock2,000USD 90.00USD 180,000SEC filing ↗
2026-04-08HENDERSON MICHAEL THOMASSale (S)Common Stock20,000USD 82.58USD 1,651,664SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAPGE
CIK0001974640
SectorHealthcare
Industry— Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
Exchange—

Data coverage

Local Form 4 history171 transaction lines from 2023-07-13 to 2026-09-03
6 P purchase lines · 131 S sale lines · 34 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.